STOCK TITAN

PharmaCyte Biotech agrees to swap warrants for 4.98M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. (PMCB) entered an agreement with Q/C Technologies, Inc. to exchange 851,304 Q/C Series G Long-Term Warrants for 4,982,272 Q/C common shares. The share count was based on the warrants’ Black-Scholes value divided by $0.3101, Q/C common stock’s closing price on the last trading day before the agreement; PharmaCyte paid no additional consideration.

As majority holder of Q/C Series H Convertible Preferred Stock, PharmaCyte consented to extending the stock’s maturity from March 2, 2027, to September 2, 2027, for no consideration. The Exchange Shares have not been registered under the Securities Act of 1933, as amended. Beginning 90 days after the exchange, PharmaCyte may demand resale registration, and Q/C must file within 30 days after receiving the demand. PharmaCyte CEO and Chairman Joshua N. Silverman also serves as Q/C’s CEO.

Filing Explained

Item 2.01 identifies the disposition as completed: PharmaCyte exchanged 851,304 Q/C warrants for 4,982,272 Q/C shares, which remain unregistered.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Warrants exchanged 851,304 warrants Q/C Series G Long-Term Warrants covered by the exchange agreement
Exchange shares 4,982,272 shares Q/C common shares to be received under the agreement
Reference closing price $0.3101 per share Q/C common stock closing price on the last trading day before the agreement; used with the Black-Scholes value to determine the Exchange Shares
Prior maturity date March 2, 2027 Q/C Series H Convertible Preferred Stock
Extended maturity date September 2, 2027 Q/C Series H Convertible Preferred Stock
Demand period 90 days after the Warrant Exchange When PharmaCyte may begin demanding a resale registration statement
Registration filing period 30 days Period for Q/C to file after receiving a demand
Series G Long-Term Warrants financial
"851,304 Series G Long-Term Warrants to purchase shares"
Black-Scholes value financial
"based on the Black-Scholes value of the Exchange Warrants"
Series H Convertible Preferred Stock financial
"majority holder of Q/C’s Series H Convertible Preferred Stock"
resale registration statement regulatory
"Q/C will be required to file a resale registration statement"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
Certificate of Designations regulatory
"an amendment to the Certificate of Designations"
A certificate of designations is a formal legal document that spells out the specific rights and rules attached to a particular class of stock, most often preferred shares. It tells investors who gets paid first, what dividends or conversion rights exist, and any voting or liquidation priorities—like an instruction sheet that decides which shareholders get preference if a company pays out or is sold. Those terms directly affect a security’s value and risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Q/C shares did PharmaCyte agree to receive for its warrants?

PharmaCyte agreed to exchange 851,304 Q/C Series G Long-Term Warrants for 4,982,272 Q/C common shares. The share count was based on the warrants’ Black-Scholes value divided by $0.3101, Q/C common stock’s closing price on the last trading day before the agreement.

How did the agreement change the maturity date of Q/C’s Series H preferred stock?

PharmaCyte consented to extending the maturity date from March 2, 2027, to September 2, 2027. PharmaCyte was the majority holder of Q/C’s Series H Convertible Preferred Stock and paid no consideration for the amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001157075 0001157075 2026-11-15 2026-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2026

 

PHARMACYTE BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada 001-40699 62-1772151
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3960 Howard Hughes Parkway, Suite 500
Las Vegas
, Nevada
89169
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code: (917) 595-2850

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, Par Value $0.0001 Per Share   PMCB  

The Nasdaq Stock Market LLC

         

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Consent and Warrant Exchange Agreement

 

On November 15, 2026, PharmaCyte Biotech, Inc. (the “Company”) entered into a Consent and Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with Q/C Technologies, Inc., formerly known as TNF Pharmaceuticals, Inc. (“Q/C”). Under the Warrant Exchange Agreement, the Company agreed to exchange 851,304 Series G Long-Term Warrants to purchase shares of Q/C’s common stock, par value $0.001 per share (the “Q/C Common Stock”), held by the Company, which were issued pursuant to that certain Securities Purchase Agreement, dated May 20, 2024, by and among Q/C and the purchasers party thereto, including the Company (such exchanged warrants, the “Exchange Warrants”), for an aggregate of 4,982,272 shares of Q/C Common Stock (the “Exchange Shares”) (the “Warrant Exchange”). The number of Exchange Shares was determined based on the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of the Q/C Common Stock on the last trading day prior to execution of the Warrant Exchange Agreement. The Company paid no additional consideration in the Warrant Exchange.

 

In addition, as majority holder of Q/C’s Series H Convertible Preferred Stock (the “Q/C Series H Preferred Stock”), the Company consented under the Warrant Exchange Agreement to an amendment to the Certificate of Designations of the Q/C Series H Preferred Stock that extends the maturity date of the Q/C Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Amendment”). The Company paid no consideration for the Series H Amendment.

 

Joshua N. Silverman, the Company’s Chief Executive Officer and Chairman of the Board of Directors, serves as the Chief Executive Officer of Q/C. The Company is also a holder of Q/C’s Series G Convertible Preferred Stock.

 

The Exchange Shares have not been registered under the Securities Act of 1933, as amended. Pursuant to the Warrant Exchange Agreement, upon the Company’s demand beginning 90 days after the Warrant Exchange, Q/C will be required to file a resale registration statement with the Securities and Exchange Commission to register the Exchange Shares for resale within 30 days after receiving such demand.

 

The foregoing description of the Warrant Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Warrant Exchange Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Consent and Warrant Exchange Agreement, dated November 15, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     
  PHARMACYTE BIOTECH, INC.
   
Date: November 19, 2026  
     
  By: /s/ Joshua N. Silverman
  Name: Joshua N. Silverman
  Title: Chief Executive Officer and President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

Filing Exhibits & Attachments

4 documents

Keep reading